Physician profile
Larry J Plundo
NPI 1902824360
$11,084.95
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,674 · 2020: $2,176 · 2021: $2,638 · 2022: $2,166 · 2023: $1,248 · 2024: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,682.05 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $1,606.43 | 2019-2023 | Farxiga, Breztri |
| Abbvie INC. | $1,181.64 | 2019-2024 | |
| Novo Nordisk INC | $1,141.21 | 2019-2023 | Rybelsus, Ozempic |
| Amgen INC. | $602.21 | 2019-2023 | Repatha, Otezla |
| Valeritas, INC. | $596.99 | 2019 | |
| Mannkind Corporation | $432.16 | 2022-2024 | Afrezza, V-Go |
| Lilly USA, LLC | $389.94 | 2019-2023 | Mounjaro |
| Amarin Pharma, INC. | $337.92 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $236.88 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $235.93 | 2019-2021 | |
| Allergan, INC. | $219.09 | 2020 | |
| Pfizer INC. | $196.25 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $186.52 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $166.84 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Plundo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.